Integrating BCMA Directed Bispecifics into the Relapsed / Refractory Myeloma Landscape

In this OncLive® Insights program, Paul Richardson, MD, is joined by Hans Lee, MD, to examine the evolving role of BCMA-directed bispecific antibodies in the treatment of relapsed or refractory multiple myeloma. The discussion focuses on patients who are triple-class exposed or refractory and face limited options with conventional therapies. Drs Richardson and Lee review the biologic rationale for targeting BCMA, compare available therapeutic platforms including CAR T-cell therapy, antibody-drug conjugates, and bispecific antibodies, and explore how these approaches are being sequenced in real-world practice. The experts highlight linvoseltamab, including key design elements and outcomes from the LINKER-MM1 trial, safety considerations such as cytokine release syndrome and infection risk, and practical aspects of step-up dosing and treatment de-escalation. The conversation also highlights challenges and opportunities in community oncology settings, offering practical insights into integrating BCMA-directed bispecifics into everyday clinical care.